Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CagriSema in Type 2 Diabetes (REIMAGINE 3)
NCT06323161Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Mar 2024
- Primary completion
- Sep 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
A Phase 3 trial of cagrilintide, semaglutide in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started Mar 2024; status: completed.
02
Drugs
cagrilintidesemaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06323161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06323161.